329 related articles for article (PubMed ID: 33297703)
1. Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Millitary Hospital Prague.
Bohoněk M; Řezáč D; Holub M
Cas Lek Cesk; 2020; 159(5):175-180. PubMed ID: 33297703
[TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
Ranganathan S; Iyer RN
Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232
[TBL] [Abstract][Full Text] [Related]
3. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
Wang Y; Huo P; Dai R; Lv X; Yuan S; Zhang Y; Guo Y; Li R; Yu Q; Zhu K
Int Immunopharmacol; 2021 Feb; 91():107262. PubMed ID: 33338863
[TBL] [Abstract][Full Text] [Related]
5. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
[TBL] [Abstract][Full Text] [Related]
6. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
7. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
8. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.
Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y
Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
10. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
[TBL] [Abstract][Full Text] [Related]
11. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
[TBL] [Abstract][Full Text] [Related]
12. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
Tang J; Grubbs G; Lee Y; Golding H; Khurana S
Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
[TBL] [Abstract][Full Text] [Related]
13. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection.
Baldeón ME; Maldonado A; Ochoa-Andrade M; Largo C; Pesantez M; Herdoiza M; Granja G; Bonifaz M; Espejo H; Mora F; Abril-López P; Armijo LKR; Pacheco V; Salazar R; Reinthaller S; Zertuche F; Fornasini M
Transfus Med; 2022 Apr; 32(2):153-161. PubMed ID: 35001439
[TBL] [Abstract][Full Text] [Related]
14. Emergence of ancient convalescent plasma (CP) therapy: To manage COVID-19 pandemic.
Dassarma B; Tripathy S; Matsabisa M
Transfus Clin Biol; 2021 Feb; 28(1):123-127. PubMed ID: 33285298
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
[TBL] [Abstract][Full Text] [Related]
16. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
19. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
[TBL] [Abstract][Full Text] [Related]
20. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
